JP6483017B2 - ナノ粒子製剤 - Google Patents

ナノ粒子製剤 Download PDF

Info

Publication number
JP6483017B2
JP6483017B2 JP2015529120A JP2015529120A JP6483017B2 JP 6483017 B2 JP6483017 B2 JP 6483017B2 JP 2015529120 A JP2015529120 A JP 2015529120A JP 2015529120 A JP2015529120 A JP 2015529120A JP 6483017 B2 JP6483017 B2 JP 6483017B2
Authority
JP
Japan
Prior art keywords
cholesteryl
lita
acid
nanoparticles
nanoparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015529120A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530382A (ja
JP2015530382A5 (OSRAM
Inventor
ベル、ジミー
ルイーズ トーマス、エリザベス
ルイーズ トーマス、エリザベス
ブロディー、レイ
サフリ アリソイル、メリズ
サフリ アリソイル、メリズ
ミラー、アンドリュー
フロスト、ガリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of JP2015530382A publication Critical patent/JP2015530382A/ja
Publication of JP2015530382A5 publication Critical patent/JP2015530382A5/ja
Application granted granted Critical
Publication of JP6483017B2 publication Critical patent/JP6483017B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015529120A 2012-08-28 2013-08-28 ナノ粒子製剤 Active JP6483017B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1215289.8A GB201215289D0 (en) 2012-08-28 2012-08-28 Nanoparticle formulation
GB1215289.8 2012-08-28
PCT/GB2013/052258 WO2014033453A1 (en) 2012-08-28 2013-08-28 Nanoparticle formulation

Publications (3)

Publication Number Publication Date
JP2015530382A JP2015530382A (ja) 2015-10-15
JP2015530382A5 JP2015530382A5 (OSRAM) 2016-10-13
JP6483017B2 true JP6483017B2 (ja) 2019-03-13

Family

ID=47045497

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529120A Active JP6483017B2 (ja) 2012-08-28 2013-08-28 ナノ粒子製剤

Country Status (8)

Country Link
US (1) US10201499B2 (OSRAM)
EP (1) EP2890365B1 (OSRAM)
JP (1) JP6483017B2 (OSRAM)
CN (1) CN104837482B (OSRAM)
AU (1) AU2013308245B2 (OSRAM)
CA (1) CA2882705C (OSRAM)
GB (1) GB201215289D0 (OSRAM)
WO (1) WO2014033453A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
RU2017127597A (ru) * 2015-01-23 2019-02-25 Темпл Юнивёрсити-Оф Дзе Коммонвелс Систем Оф Хайе Эдьюкейшен Применение короткоцепочечных жирных кислот для профилактики рака
CN106551902B (zh) * 2015-09-17 2020-07-03 阿赖耶识（上海）生物技术有限公司 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用
CN105669964B (zh) * 2016-03-04 2017-11-21 博瑞生物医药（苏州）股份有限公司 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
AU2018236190B2 (en) * 2017-03-13 2025-02-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
CN110891982B (zh) 2017-04-17 2023-12-22 芝加哥大学 向肠道递送短链脂肪酸以用于人体保健和疾病治疗的聚合物材料
CN107049954A (zh) * 2017-06-12 2017-08-18 杭州普施康生物科技有限公司 一种药物组合及其制备方法和用途
CN110192651A (zh) * 2019-05-31 2019-09-03 浙江工业大学 一种利用大豆分离蛋白负载植物甾醇酯的纳米乳液的制备方法
CN111426659B (zh) * 2020-03-24 2023-06-06 深圳唯公生物科技有限公司 磁性荧光编码微球及其制备方法
US20250269003A1 (en) * 2022-04-22 2025-08-28 University Of Virginia Patent Foundation Nano-enhanced vaccine
KR20250107214A (ko) * 2022-11-10 2025-07-11 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 간질환 또는 간장애의 치료 또는 예방 방법
CN118105524B (zh) * 2024-03-14 2024-11-22 南京鼓楼医院 一种靶向肠上皮细胞的焦亡抑制剂药物递送系统及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
DE69727384T2 (de) * 1996-05-24 2004-11-04 IC-VEC Ltd. Polykatonische sterin-derivate zur transfektion
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
IT1303787B1 (it) * 1998-11-25 2001-02-23 Maria Rosa Gasco "nanosfere lipidiche solide atte ad una rapida internalizzazione nellecellule"
EP1140022B8 (en) * 1998-12-18 2008-10-15 Hadasit Medical Research Services & Development Ltd. Method of administering a compound to multi-drug resistant cells
US6387952B1 (en) 2000-09-19 2002-05-14 Arco Chemical Technology L.P. Method of treating gastrointestinal disorders, particularly colitis
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
WO2006076734A2 (en) 2005-01-14 2006-07-20 Medical College Of Georgia Research Institute Prodrugs of short-chain fatty acids and treatment methods
US9315532B2 (en) 2005-05-24 2016-04-19 The Johns Hopkins University Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof
ITMI20051024A1 (it) 2005-06-01 2006-12-02 Maria Rosa Gasco Nuovo uso di nanoparticelle lipidiche solide
US7700567B2 (en) * 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2673622A1 (en) 2006-12-22 2008-07-03 Imuthes Limited Lipid
CA2742689A1 (en) * 2008-11-17 2010-05-20 Enzon Pharmaceuticals, Inc. Branched cationic lipids for nucleic acids delivery system

Also Published As

Publication number Publication date
EP2890365A1 (en) 2015-07-08
GB201215289D0 (en) 2012-10-10
AU2013308245B2 (en) 2018-03-29
EP2890365B1 (en) 2019-11-20
CN104837482A (zh) 2015-08-12
CN104837482B (zh) 2018-09-18
CA2882705C (en) 2021-06-22
AU2013308245A1 (en) 2015-04-09
JP2015530382A (ja) 2015-10-15
US20150224054A1 (en) 2015-08-13
US10201499B2 (en) 2019-02-12
WO2014033453A1 (en) 2014-03-06
HK1211862A1 (en) 2016-06-03
CA2882705A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
JP6483017B2 (ja) ナノ粒子製剤
JP5883797B2 (ja) 腫瘍の磁気共鳴画像化法のためのリポソームナノ粒子
Cheong et al. Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system
KR102210774B1 (ko) 세미플루오로탄소 화합물을 함유하는 조영제
US9170257B2 (en) Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
Li et al. Mr and fluorescent imaging of low-density lipoprotein receptors1
JP2004511426A5 (OSRAM)
US20110223103A1 (en) Multimodal Imaging of Atherosclerotic Plaque Targeted to LOX-1
WO2022122054A1 (zh) 提高阿霉素肿瘤主动靶向性和肾脏保护的纳米结构脂质制剂及制备方法
JP2005534718A (ja) カチオンキャリヤー系において診断化合物および治療化合物を安定化させる新規方法
van Tilborg et al. Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes
US20140161733A1 (en) Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
CN1980671B (zh) 含有水难溶性喜树碱的脂质体制剂
Maiseyeu et al. Detection of macrophages via paramagnetic vesicles incorporating oxidatively tailored cholesterol ester: an approach for atherosclerosis imaging
CN113307824B (zh) 一种双亲性材料及其在制备脂质体中的应用
HK1211862B (en) Nanoparticle formulation
WO2012153616A1 (ja) 標的細胞移行能を有する脂質膜構造体、その製造方法および標的細胞において効果を示す物質のスクリーニング方法
US20240181062A1 (en) Red-shifted photolipids and nanoparticles formed from same
Yu et al. Targeted delivery of empagliflozin via glycyrrhetinic-acid-modified lipid nanoparticles for metabolic dysfunction–associated steatotic liver disease therapy
US20160129136A1 (en) Novel compositions and uses thereof
JPWO2001082977A1 (ja) 疎水性ヨード化合物を含むリポソーム
JP2006241107A (ja) 目的物質の脳毛細血管内皮細胞への取り込みを亢進させるための組成物
JP2005170807A (ja) 抗体を含むリポソーム
Wang et al. Self-association of endothelin-1 with sterically stabilized phospholipid nanomicelles amplifies its hemodynamic effects in rats

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150507

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180828

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190213

R150 Certificate of patent or registration of utility model

Ref document number: 6483017

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250